Your browser doesn't support javascript.
loading
Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study.
Onwuamah, Chika K; Okpokwu, Jonathan; Audu, Rosemary; Imade, Godwin; Meloni, Seema T; Okwuraiwe, Azuka; Chebu, Philippe; Musa, Adesola Z; Chaplin, Beth; Dalhatu, Ibrahim; Agbaji, Oche; Samuels, Jay; Ezechi, Oliver; Ahmed, Mukhtar; Odaibo, Georgina; Olaleye, David O; Okonkwo, Prosper; Salako, Babatunde Lawal; Raizes, Elliot; Yang, Chunfu; Kanki, Phyllis J; Idigbe, Emmanuel O.
Afiliação
  • Onwuamah CK; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria. chikaonwuamah@yahoo.com.
  • Okpokwu J; Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
  • Audu R; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
  • Imade G; Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
  • Meloni ST; Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Okwuraiwe A; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
  • Chebu P; APIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
  • Musa AZ; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
  • Chaplin B; Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Dalhatu I; Centers for Disease Control-Nigeria, Abuja, FCT, Nigeria.
  • Agbaji O; Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
  • Samuels J; APIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
  • Ezechi O; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
  • Ahmed M; Centers for Disease Control-Nigeria, Abuja, FCT, Nigeria.
  • Odaibo G; University of Ibadan, Ibadan, Oyo State, Nigeria.
  • Olaleye DO; University of Ibadan, Ibadan, Oyo State, Nigeria.
  • Okonkwo P; APIN Public Health Initiative Nigeria, Ltd./Gte, Abuja, FCT, Nigeria.
  • Salako BL; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
  • Raizes E; Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Yang C; Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Kanki PJ; Harvard T. H. Chan School of Public Health, Boston, MA, USA.
  • Idigbe EO; Microbiology Department, Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, 6 Edmund Crescent, Yaba, Lagos, 101212, Nigeria.
BMC Microbiol ; 20(1): 17, 2020 01 20.
Article em En | MEDLINE | ID: mdl-31959116
ABSTRACT

BACKGROUND:

We identified a HIV-positive cohort in virologic failure (VF) who re-suppressed without drug switch. We characterized their drug resistance mutations (DRM) and adherence profiles to learn how to better manage HIV drug resistance. A retrospective cohort study utilizing clinical data and stored samples. Patients received ART at three Nigerian treatment centres. Plasma samples stored when they were in VF were genotyped.

RESULT:

Of 126 patients with samples available, 57 were successfully genotyped. From ART initiation, the proportion of patients with adherence ≥90% increased steadily from 54% at first high viral load (VL) to 67% at confirmed VF, and 81% at time of re-suppressed VL. Sixteen (28%) patients had at least one DRM. Forty-six (81%) patients had full susceptibility to the three drugs in their first-line (1 L) regimen. Thirteen (23%) were resistant to at least one antiretroviral drug but three were resistant to drugs not used in Nigeria. Ten patients had resistance to their 1 L drug(s) and six were fully susceptible to the three drugs in the recommended second-line regimen.

CONCLUSION:

This cohort had little drug resistance mutations. We conclude that if adherence is not assured, patients could exhibit virologic failure without having developed mutations associated with drug resistance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Farmacorresistência Viral / Mutação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Farmacorresistência Viral / Mutação Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Africa Idioma: En Ano de publicação: 2020 Tipo de documento: Article